Stockscreener 앱 받기
4.945
0.10%
0.025
Ardelyx Inc 주식(ARDX)의 최신 뉴스
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Ardelyx Executives to Present at Piper Sandler Healthcare Conference | ARDX Stock News - StockTitan
Jefferies optimistic on Ardelyx stock as management navigates reimbursement changes - Investing.com
US Penny Stocks To Monitor In November 2024 - Simply Wall St
Ardelyx, Inc. (NASDAQ:ARDX) Short Interest Up 5.1% in October - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Ardelyx (NASDAQ:ARDX) Shares Gap UpTime to Buy? - MarketBeat
Janus Henderson Group PLC's Strategic Reduction in Ardelyx Inc H - GuruFocus.com
Director David Mott Acquires 215,868 Shares of Ardelyx Inc (ARDX) - GuruFocus.com
Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability (NASDAQ:ARDX) - Seeking Alpha
HC Wainwright Has Bearish Forecast for Ardelyx Q1 Earnings - MarketBeat
Ardelyx (NASDAQ:ARDX) Rating Lowered to “Neutral” at HC Wainwright - Defense World
Ardelyx shares downgraded amid sales concerns for XPHOZAH By Investing.com - Investing.com Australia
Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop - Seeking Alpha
Ardelyx (NASDAQ:ARDX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Ardelyx shares downgraded amid sales concerns for XPHOZAH - Investing.com India
Ardelyx (NASDAQ:ARDX) Lowered to Neutral Rating by HC Wainwright - MarketBeat
Ardelyx chief development officer sells shares worth $165,743 - Investing.com India
Ardelyx chief development officer sells shares worth $165,743 By Investing.com - Investing.com Australia
David P. Rosenbaum Sells 27,171 Shares of Ardelyx, Inc. (NASDAQ:ARDX) Stock - MarketBeat
Ardelyx Beats Q3 Sales Estimates, Shares Climb - MSN
Ardelyx Loses Bid to Block HHS Classification of Kidney Drug - Bloomberg Law
Ardelyx tumbles as lawsuit against CMS dismissed over Xphozah (update) - MSN
Ardelyx Responds to District Court Decision Granting Motion to Dismiss - The Manila Times
Ardelyx (NASDAQ:ARDX) Shares Gap DownTime to Sell? - MarketBeat
Ardelyx ‘disappointed’ by court decision granting motion to dismiss - TipRanks
Ardelyx Stock Alert: Court Dismisses CMS Lawsuit, XPHOZAH Access Concerns Mount | ARDX Stock News - StockTitan
Ardelyx falls after court dismisses lawsuit against CMS over company's kidney disease drug - XM
Ardelyx chief development officer sells $161,673 in stock - Investing.com
Ardelyx chief development officer sells $161,673 in stock By Investing.com - Investing.com Canada
(ARDX) Investment Analysis - Stock Traders Daily
Citigroup Lowers Ardelyx (NASDAQ:ARDX) Price Target to $10.00 - Defense World
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference - ForexTV.com
Ardelyx (ARDX) Leadership to Present at Jefferies London Healthcare Conference 2024 | ARDX Stock News - StockTitan
What is Wedbush’s Forecast for Ardelyx FY2026 Earnings? - Defense World
ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Inve - GuruFocus.com
Ardelyx (NASDAQ:ARDX) Price Target Lowered to $10.00 at Citigroup - MarketBeat
Wedbush Has Negative Outlook for Ardelyx FY2026 Earnings - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2024 Earnings Call Transcript - MSN
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St
Ardelyx (NASDAQ:ARDX) Stock Price Up 7.3% – Here’s Why - Defense World
Allspring Global Investments Holdings LLC Sells 19,212 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Lost Money on Ardelyx, Inc.(ARDX)? Join Class Action Suit Seekin - GuruFocus.com
Ardelyx Third Quarter 2024 Earnings: US$0.003 loss per share (vs US$0.03 profit in 3Q 2023) - Yahoo Finance
Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics - MSN
Ardelyx (NASDAQ:ARDX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Earnings call: Ardelyx reports solid growth amid Medicare challenges - Investing.com
Earnings call: Ardelyx reports solid growth amid Medicare challenges By Investing.com - Investing.com Canada
Ardelyx (NASDAQ:ARDX) Shares Up 7.3%Should You Buy? - MarketBeat
Ardelyx Target of Unusually High Options Trading (NASDAQ:ARDX) - MarketBeat
Ardelyx Surpasses Q3 Revenue Estimates - The Motley Fool
Ardelyx CEO Michael Raab sells $147,740 in stock By Investing.com - Investing.com Australia
Ardelyx Inc (ARDX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Amidst ... - Yahoo Finance
Ardelyx CEO Michael Raab sells $147,740 in company stock By Investing.com - Investing.com Canada
Ardelyx Reports Robust Q3 2024 Revenue Growth - TipRanks
0.42%
0.16%
자본화:
|
볼륨(24시간):